AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29190319
Drug: Pelvic radiotherapy
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiotherapy (RT) with concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Trial: 25687834
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (autogenous split‐thickness skin implant)
Trial: 23370075
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G-GR) 1800 mg (600 mg AM/1200 mg PM) for 14 weeks
Trial: 24521776
Drug: Fluvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (80 mg/d)
Trial: 1323501
Drug: Ossein-hydroxyapatite compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ossein-hydroxyapatite compound (OHC) 6.46 g daily for 6 months
Trial: 1323501
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bone protective treatment)
Trial: 26659550
Drug: Lurasidone 60
RxNorm normalized name: lurasidone 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 60 mg/day
Trial: 27611311
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) patches
Trial: 17884396
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate brachytherapy as a boost after external beam chemoradiotherapy
Trial: 18160753
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C
Trial: 12115017
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg vitamin C
Trial: 11789184
Drug: Puerarin 400
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin 400 mg per day intravenously dripping
Trial: 9092223
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n = 834)
Trial: 6540129
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (i.v. IgG)
Trial: 30370686
Drug: Proximal metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal metformin (1000 mg) + distal saline
Trial: 30370686
Drug: Distal metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal metformin (1000 mg) + proximal saline
Trial: 28524358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no-treatment assessment-only)
Trial: 25015544
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor monotherapy (darunavir/ritonavir or lopinavir/ritonavir)
Trial: 25015544
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug therapy (two nucleos(t)ides)
Trial: 20397453
Drug: Drug control
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug control group
Trial: 14563515
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy with primary prophylaxis using hemopoietic growth factors
Trial: 7769318
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg of base/kg during 3 days or 10 mg of base/kg in one dose) plus primaquine (10 mg/kg during 28 days or 2.5 mg/kg during 3 days)
Trial: 7769318
Drug: Halofantrine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (24 mg base/kg in 12 h)
Trial: 2182613
Drug: Phosphatidylcholine (lecithin)
RxNorm normalized name: phosphatidylcholine, soybean
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine (lecithin) 20 g/day
Trial: 311979
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Peptide-PABA
Trial: 311979
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Peptide-PABA
Trial: 19070758
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (20 mg/kg)
Trial: 8023802
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of supplements that did not contain carotene
Trial: 28533151
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) with salvage radiation therapy (SRT)
Trial: 28533151
Drug: ADT use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT use predictors: presurgery PSA >20 ng/ml (AOR = 1.34, P = 0.002; 36.7% vs. 29.6%), positive margins (AOR = 1.29, P = 0.001; 34.9% vs. 27.8%), Gleason scores (Gleason 3+4 AOR = 1.53; 21.3%, 4+3 AOR = 2.40; 32.0%, 8 to 10 AOR = 4.49; 49.2% vs. 2 to 6; P≤0.005 for all; 13.2%), pathologic T stages (T3a AOR = 1.46; 30.9%, T3b AOR = 2.50; 47.6%, T4 AOR = 4.14; 60.9% vs. T2; P<0.001 for all; 19.1%).
Trial: 18937325
Drug: DTP vaccine
RxNorm normalized name: DTP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine (three doses administered)
Trial: 10193254
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 1 ppm
Trial: 3396485
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course prophylaxis (2g cefotaxime at anaesthesia plus 7 doses of 1g 12‐hourly)
Trial: 3396485
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (short and long course)
Trial: 29119704
Drug: RP5063 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP5063 (10 mg fasting, 15 mg fed/fasting)
Trial: 29119704
Drug: RP5063 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP5063 (10, 20, 50, and 100 mg fed)
Trial: 29119704
Drug: RP5063 (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP5063 (single-dose study)
Trial: 28374849
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg every 2 weeks
Trial: 20642207
Drug: FAHF‐2 (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAHF‐2 (2.2 g, 3 times a day for 7 days)
Trial: 20642207
Drug: FAHF‐2 (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAHF‐2 (3.3 g, 3 times a day for 7 days)
Trial: 20642207
Drug: FAHF‐2 (6.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAHF‐2 (6.6 g, 3 times a day for 7 days)
Trial: 12682474
Drug: Stress doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress doses of hydrocortisone (100 mg before induction of anesthesia, then 10 mg/hr for 24 hrs, 5 mg/hr for 24 hrs, 3 x 20 mg/day, and 3 x 10 mg/day)
Trial: 9184782
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (15 mg/day)
Trial: 8197889
Drug: Minimal contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal contact self-help treatment control
Trial: 3581712
Drug: 3 weeks'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks' anticoagulation with heparin and warfarin
Trial: 3581712
Drug: 6 weeks'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks' anticoagulation with heparin and warfarin
Trial: 18604331
Drug: Celecoxib (accumulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (accumulated dose of 400 mg)
Trial: 18604331
Drug: Meloxicam (accumulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (accumulated dose of 15 mg)
Trial: 16311277
Drug: Magnesium 40
RxNorm normalized name: Magnesium 400mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium 40 mg kg(‐1) bolus followed by magnesium 10 mg kg(‐1) h(‐1) infusion
Trial: 16311277
Drug: Magnesium 40
RxNorm normalized name: Magnesium 400mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium 40 mg kg(‐1) bolus followed by magnesium 20 mg kg(‐1) h(‐1) infusion
Trial: 3083718
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg nicardipine
Trial: 7762855
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg diltiazem
Trial: 3940258
Drug: Lidamidine 12
RxNorm normalized name: lidamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidamidine 12 mg
Trial: 3940258
Drug: Lidamidine 18
RxNorm normalized name: lidamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidamidine 18 mg
Trial: 30355119
Drug: Prior intravenous
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior intravenous thrombolysis
Trial: 22219343
Drug: I.V. acetazolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. acetazolamide (ACZ) 10 mg kg⁻¹
Trial: 18383657
Drug: Sucking ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucking ice during chemotherapy
Trial: 18383657
Drug: Analgesics (especially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics (especially morphine)
Trial: 12753443
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with bupivacaine 0.22% 4 mg.kg‐1 (1.8 ml.kg‐1) and morphine 150 microg x kg‐1
Trial: 8565196
Drug: MethaSite (0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MethaSite (0.1% fluorometholone gel‐forming suspension)
Trial: 8565196
Drug: FML S.O.P.
RxNorm normalized name: FML S.O.P.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FML S.O.P. (0.1% fluorometholone ointment)
Trial: 2016630
Drug: Prophylactic vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic vancomycin 15 mg/kg every 12 hours from day -2 until resolution of neutropenia or until the first episode of fever
Trial: 7224109
Drug: Rechallenge with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rechallenge with the same allergen or a dissimilar challenging agent
Trial: 7224109
Drug: Rechallenge with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rechallenge with an unrelated allergen or compound 48/80
Trial: 17304143
Drug: Mesalazine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (4 g/day)
Trial: 28687413
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg three times per week for 48 weeks
Trial: 19507456
Drug: e/Tablet electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e/Tablet electronic format
Trial: 16550416
Drug: Psychiatric day‐hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric day‐hospital treatment
Trial: 9820992
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment to lower serum cholesterol
Trial: 2572495
Drug: Sulfasalazine prophylaxis
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine prophylaxis (3 g daily for at least 2 years)
Trial: 336304
Drug: 1.05 mg
RxNorm normalized name: thiamine 1.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.05 mg atropine
Trial: 18782903
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg terbutaline
Trial: 31754238
Drug: 8-month daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-month daily after-school aerobic exercise program (40 min/day, n=90)
Trial: 31718297
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy in addition to optimal medical therapy
Trial: 17003303
Drug: Intensive multifactorial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial pharmacological treatment
Trial: 12770610
Drug: AIT-082 100
RxNorm normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIT-082 100 mg/day
Trial: 12770610
Drug: AIT-082 500
RxNorm normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIT-082 500 mg/day
Trial: 12770610
Drug: AIT-082 2000
RxNorm normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIT-082 2000 mg/day
Trial: 12770610
Drug: AIT-082 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIT-082 (all doses)
Trial: 9298381
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous drip infusion for 12-24 hours
Trial: 9298381
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative intravenous drip infusion
Trial: 3793337
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (CC)
Trial: 27449404
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml)
Trial: 27117440
Drug: Testosterone solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone solution 2% (T-sol)
Trial: 24642148
Drug: tamsulosin (0.4mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin (0.4mg, three doses: 14 and 2 hours before, and 10 hours after surgery)
Trial: 22181338
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) 120 mg/day for one month (n=10)
Trial: 17947726
Drug: Capecitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,000 mg/m2 twice daily for 2 weeks, followed by a 1-week break) + Erlotinib (150 mg daily)
Trial: 15678055
Drug: TP‐10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP‐10 (10 mg/kg)
Trial: 12841536
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) therapy, 10-30 mg for the first month and 5-10 mg from the second to the twelfth month.
Trial: 12841536
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 2) with normal serum TSH at the end of the first month of MMI therapy.
Trial: 10812235
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (4000 PFU)
Trial: 10812235
Drug: Inactivated VZV
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated VZV vaccine (equal volume to live vaccine)
Trial: 9678125
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives started on the first day of menses (day 1 group)
Trial: 9678125
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives started on the fifth day after the onset of menses (day 5 group)
Trial: 1497039
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (larger dose increments of oxytocin)
Trial: 1497039
Drug: Traditional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional group (standard dose increments of oxytocin)
Trial: 29497121
Drug: Rupatadine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 40 mg daily
Trial: 27236887
Drug: Yiqi Fumai
RxNorm normalized name: Aspergillus fumigatus allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Fumai Lyophilized Powder (5.2 g in 500 mL normal saline)
Trial: 23479999
Drug: Furasidine potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furasidine potassium (furamag) 50 mg t.i.d. for 7 days
Trial: 23479999
Drug: Phosphomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphomycin trometamol (monural) 3 g single dose for pulse therapy
Trial: 20459883
Drug: Aripiprazole at
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole at 5‐15 mg/d
Trial: 16253975
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg twice daily) for 6 months
Trial: 15576654
Drug: RAS blockers
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RAS blockers (RASb) and acetylsalicylic acid (ASA)
Trial: 7754886
Drug: Bowel cleansing
RxNorm normalized name: Dulcolax Bowel Cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel cleansing with laxatives and allowed to eat (Group 1)
Trial: 7754886
Drug: Bowel cleansing
RxNorm normalized name: Dulcolax Bowel Cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel cleansing with laxatives and liquid supper followed by fasting (Group 2)
Trial: 7754886
Drug: Laxatives before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxatives before examination (Groups 1 and 2 combined)
Trial: 7754886
Drug: No laxatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No laxatives (Groups 3 and 4 combined)
Trial: 6986827
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg of body weight per day) with prednisone (60 mg per day)
Trial: 6986827
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with prednisone (60 mg per day)
Trial: 31075401
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment group (cotrimoxazole 59.5%, quinolones 21.4%)
Trial: 31075401
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment group
Trial: 31075401
Drug: Carbapenem treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenem treatment
Trial: 30716802
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus voice therapy (Group B)
Trial: 30716802
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (Group A)
Trial: 26462480
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate 1 mg/month
Trial: 26462480
Drug: Oral risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate 2.5 mg/day
Trial: 24856782
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide adjuvanted HNVAC vaccine
Trial: 24856782
Drug: Non-adjuvanted HNVAC
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted HNVAC vaccine
Trial: 22114792
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (EPA 510 mg + DHA 340 mg)
Trial: 22114792
Drug: Placebo (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (850 mg)
Trial: 19461257
Drug: Enhanced community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced community treatment
Trial: 11680399
Drug: Ropivacaine infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine infiltration 1.5 mg/ml plus adrenaline 1/200,000 in normal saline 100 ml
Trial: 11680399
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 100 ml plus adrenaline 1/200,000
Trial: 3311191
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of CyA following ATG treatment (group CyA)
Trial: 3311191
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment including ATG (group STD)
Trial: 3311191
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of CyA
Trial: 25696967
Drug: basal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basal therapy